Literature DB >> 10512611

Short-term and long-term treatment for bipolar patients: beyond the guidelines.

J Mendlewicz1, D Souery, S K Rivelli.   

Abstract

This clinical review considers the different symptomatic forms of bipolar disorders and the influence of the clinical subtype on treatment. Therapy is required both to manage the various types of acute episodes of mania or depression and to prevent recurrence. For the latter purpose, continuous long-term or even lifetime prophylaxis may be required, continuing on after control of the acute episode. In this context, the roles and potential side-effects of lithium, divalproex sodium and carbamazepine, alone and in combination, are summarized, along with the proper use of antipsychotic drugs. The selection of mood-stabilizing agent or drug combination depends on the clinical manifestations of bipolar disorder, family history and previous treatment history of the patient. Particular caution must be exercised in those with a history of antidepressant-induced switches; many such patients appear prone to course aggravation and even rapid-cycling and will often need combined mood-stabilizer combinations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512611     DOI: 10.1016/s0165-0327(99)00125-1

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  3 in total

Review 1.  Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease.

Authors:  Karen E Stewart; James L Levenson
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

2.  Mixed versus manic bipolar disorder: a comparison of demographic, symptomatic, and treatment differences.

Authors:  Nurun N Shah; Patricia M Averill; Andrew Shack
Journal:  Psychiatr Q       Date:  2004

3.  Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium.

Authors:  Hubertus Himmerich; Dagmar Koethe; Andreas Schuld; Alexander Yassouridis; Thomas Pollmächer
Journal:  Psychopharmacology (Berl)       Date:  2004-11-25       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.